{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BRCTF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRCTF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCTF\",,,,,undefined,":{"symbol":"BRCTF","market":"US","secType":"STK","nameCN":"BIOARCTIC AB","latestPrice":20.37,"timestamp":1746820800000,"preClose":20.37,"halted":0,"volume":0,"delay":15,"floatShares":52512937,"shares":88059985,"eps":-0.129444,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-09 16:00:00 EDT Delay","open":20.37,"high":20.37,"low":20.37,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.129444,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747056600000},"marketStatusCode":1,"adr":0,"exchange":"PINK LIMITED","adjPreClose":20.37,"volumeRatio":0.3263706293587614},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCTF\",,,,,undefined,":{"symbol":"BRCTF","floatShares":52512937,"roa":"-12.49%","roe":"-18.24%","lyrEps":0.258365,"volumeRatio":0.3263706293587614,"shares":88059985,"dividePrice":0,"high":20.37,"amplitude":0,"preClose":20.37,"low":20.37,"week52Low":12.9435,"pbRate":"19.69","psRate":"68.47","week52High":24.8,"institutionHeld":0,"latestPrice":20.37,"eps":-0.129444,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.129444,"open":20.37,"prevYearClose":18.3,"prevWeekClose":20.37,"prevMonthClose":19.71,"prevQuarterClose":18.12,"fiveDayClose":20.37,"twentyDayClose":16.53,"sixtyDayClose":20.245},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BRCTF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRCTF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526388195","title":"High Growth Tech Stocks To Watch In Europe April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526388195","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526388195?lang=en_us&edition=fundamental","pubTime":"2025-04-09 13:08","pubTimestamp":1744175335,"startTime":"0","endTime":"0","summary":"As European markets grapple with the fallout from higher-than-expected U.S. trade tariffs, which have led to significant declines in major indices like the STOXX Europe 600 and Germany's DAX, investors are keenly observing how these developments might impact high-growth tech stocks in the region. In such volatile conditions, a good stock is often characterized by its ability to demonstrate resilience through innovation and adaptability while maintaining strong fundamentals amidst broader economic uncertainties.OB:CRAYN Earnings and Revenue Growth as at Apr 2025. Overview: BioArctic AB  is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK15.09 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-050855304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BRCTF","BK4139","HMNTY","CRAYF"],"gpt_icon":0},{"id":"2524219948","title":"The European Commission refers lecanemab decision to Appeal Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2524219948","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524219948?lang=en_us&edition=fundamental","pubTime":"2025-04-01 18:17","pubTimestamp":1743502620,"startTime":"0","endTime":"0","summary":"STOCKHOLM, April 1, 2025 /PRNewswire/ --BioArctic AB's   partner Eisai today announced that the European Commission  has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Committee.If the marketing authorization application for lecanemab is approved, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Leqembi is already approved in the US, Japan, China, Great Britain and other markets.Lecanemab is approved in the U.S., Japan, China, United Kingdom, and several other markets for the treatment of mild cognitive impairment  due to Alzheimer's disease  and mild AD dementia. Lecanemab's approvals in these countries, as well as the CHMP's positive opinion in November 2024, were primarily based on Phase 3 data from Eisai's global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai has also submitt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/european-commission-refers-lecanemab-decision-101700021.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-commission-refers-lecanemab-decision-101700021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4588","MAA","MCI","EC","BK4215","BK4201","CHMP","BK4139","BK4585","BRCTF"],"gpt_icon":0},{"id":"2522316327","title":"3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2522316327","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522316327?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:05","pubTimestamp":1743069934,"startTime":"0","endTime":"0","summary":"As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a landscape marked by trade-related uncertainties and inflation concerns. In this environment, stocks with high insider ownership can offer an appealing level of confidence, as insiders often have unique insights into their companies' potential for growth and resilience against economic headwinds.Top 10 Growth Companies With High Insider Ownership In Europe. Pharma Mar exhibits strong growth potential with its earnings forecasted to grow significantly at 40.8% annually, outpacing the Spanish market. Despite a recent decline in sales, net income surged to 26.13 million from 1.14 million year-on-year, indicating high-quality earnings. The company trades at a substantial discount of 47.4% below estimated fair value and maintains a volatile share price but benefits from high insider ownership and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-european-growth-stocks-insider-100534193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHMMF","BRCTF","FBGGF","FBGBY"],"gpt_icon":0},{"id":"2520096935","title":"BioArctic receives Orphan Drug Designation for exidavnemab the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2520096935","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520096935?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:54","pubTimestamp":1742234040,"startTime":"0","endTime":"0","summary":"STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB   announced today that the US FDA Office of Orphan Products Development  hasgranted orphan drug designation  to exidavnemab for the treatment of Multiple System Atrophy , providing incentives for the development of treatments for rare diseases with a high medical need.Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which controls several basic functions, such as breathing, digestion and bladder control. Currently there is no cure and no available treatment to slow its progression.About MSA Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is a synucleinopathy, a group of neurodegenerative dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909916.SGD","LU2125909759.SGD","LU1923622291.USD","BIOA","LU2211815571.USD","MSA","ODD","LU0728928796.USD","BK4007","LU0757428866.USD","LU1815336091.USD","LU0053671581.USD","BRCTF","BK4183","BK4143"],"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRCTF\",params:#limit:5,,,undefined,":[{"date":"2024-05-17","symbol":"BRCTF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715932800000,"name":null,"time":"","dateTimestamp":1715918400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRCTF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRCTF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1730779200000}}}